



ANRS Emerging infectious diseases

Supporting research to
prevent, understand and
treat infectious diseases

A national research agency for infectious and emerging pathogens

➤ A central role in infectious disease research for over 35 years

ANRS Emerging infectious diseases (ANRS MIE), an independent agency within Inserm, supports, evaluates, coordinates and finances research on HIV/AIDS, viral hepatitis, sexually transmitted infections, tuberculosis, and emerging and re-emerging infectious diseases. It prepares the scientific response to the challenges posed by these diseases.

1988

HIV/AIDS crisis

ANRS is created to respond to the emergency, structure and finance research.

1999-2019

The agency's activities expand to include other pathogens: hepatitis, sexually transmitted infections (STIs) and tuberculosis.

2021

COVID-19 crisis

The agency is tasked with coordinating the response to emerging infectious diseases and becomes ANRS MIE.

Creation of ANRS MIE Emerging Infectious Diseases

Emerging infectious diseases



HIV



Viral hepatitis



Tuberculosis



STI



➤ First-line engagement in crisis preparation and response

ANRS MIE is a key player in supporting and structuring research in the field of future infectious threats.

It plays a full role in implementing the National Acceleration Strategy "Emerging Infectious Diseases and Nuclear, Radiological, Biological and Chemical Threats" (EIDs and NRBC threats), defined under the France 2030 plan.

- ANRS MIE is responsible for the scientific steering and implementation of the Emerging Infectious Diseases Priority Research Program and Equipment ("PEPR MIE").
- As part of Measure 6 of the national strategy "EIDs and NRBC threats", the agency coordinates the establishment of research platforms: EMERGEN 2.0, OPEN-ReMIE, I-REIVAC.



ANRS MIE also manages:

- the call for hospital-based clinical research projects on emerging infectious diseases ("ReCH-MIE") for the General Directorate of Healthcare Provision ("DGOS");
- the "Emergences PRFI" call for projects, intended to support collaborative research projects between French teams and research teams from low- and middle-income countries (LMICs).

ANRS MIE makes a decisive contribution to the response to epidemic crises.

In the event of epidemic outbreaks in France and worldwide, due to the emergence or re-emergence of a pathogen, the agency triggers a procedure proportionate to the health crises.

Since its creation, this system has been implemented several times:

- COVID-19 pandemic (Sars-CoV-2);
- Mpox epidemics (2022, 2024);
- Marburg virus haemorrhagic fevers (Equatorial Guinea, 2023; Tanzania, 2024);
- West Nile virus and Usutu virus (2023, as part of surveillance in *Nouvelle-Aquitaine*);
- Oropouche virus and avian influenza H5N1 (2024);
- Sudan Ebola haemorrhagic fever (2025);
- Chikungunya (2025).


Leading, financing and structuring: three major levers of action

➤ Leading research

ANRS MIE pursues an active research coordination policy to support project creation and development, and strengthen collaboration between researchers, institutions and patient associations.

These committees bring together French and international experts from all research institutions: national bodies, universities, university hospitals/centres, as well as institutions committed to the "One Health" approach.

In total, **24 scientific coordination groups** structure the dynamics driven by the agency: broken down into **networks, coordinated actions (CAs) or working groups**.



Objective: promote collaborations, mobilise new teams, identify scientific priorities and implement structuring projects.

Learn more about scientific coordination groups



<https://anrs.fr/en/scientific-research/scientific-facilitation-groups/>

➤ Financing research

ANRS MIE runs a differentiated range of calls for projects (CFPs) tailored to infectious diseases, whether endemic, emerging or linked to health crises:

- annual generic and targeted CFPs with international scope, on HIV, hepatitis, tuberculosis and STIs;
- CFPs for structuring projects in the context of crisis preparedness ("PEPR MIE");
- a CFP focused on clinical research issues ("ReCH-MIE");
- a CFP "Emergences PRFI" aimed at supporting research in low- and middle-income countries;
- transnational CFPs, in collaboration with leading international scientific partners (EDCTP, South Africa, Brazil, Germany).

Objective: to finance a differentiated range of specific calls for projects tailored to endemic and emerging infectious diseases.

Discover the calls for projects



<https://anrs.fr/en/funding/all-calls-for-proposals/>

➤ Structuring research

To support the structuring of research on infectious diseases, in France and internationally, ANRS MIE finances, coordinates and supports reference networks, cohorts and platforms designed to be both sustainable and responsive in times of crisis.



Community stakeholders at the heart of the agency's work

Patient associations are fully integrated into the operation of the agency. Today, more than 20 patient associations actively collaborate with researchers in the research coordination authorities

Its actions include:

- the financing and management of a dense network of hospital-based clinical research sites in France, supported by 80 clinical and biological study monitors, as well as methodology and management centres ("CMG");
- the financing and coordination of an international network of virology and clinical pharmacology, mobilising several dozen laboratories in France and abroad;
- financing and support for national and international cohorts covering various pathologies: HIV, hepatitis, tuberculosis, dengue fever, chikungunya, Lassa fever, etc.;
- the coordination of three major infrastructures under the MIE Acceleration Strategy:
 - I-REIVAC for vaccinology in partnership with AP-HP (Greater Paris University Hospitals);
 - OPEN-ReMIE for therapeutic clinical research with *Hospices Civils de Lyon*;
 - EMERGEN for genomic monitoring with *Santé publique France* (French Public Health Agency) and Anses.

Objective: to provide research communities with robust and adapted infrastructure, in order to optimise research efforts on infectious diseases and strengthen crisis response capacity.

Action at international level in support of global health

➤ A resolutely European strategy

Europe is essential to the structuring of robust, coordinated and responsive research in the face of health crises. ANRS MIE actively contributes to this by coordinating several measures and participating in major projects at the European level.

Its main actions include:

- **coordination of the European Be Ready Now partnership for pandemic preparedness:**
 - development of a strategic research and innovation agenda, including in times of crisis;
 - launching transnational calls for projects;
- support for European research infrastructure;
- management of the Proact EU-Response clinical research network, dedicated to respiratory viruses;
- participation in the European Vaccine Hub (EVH) clinical research network in vaccinology via I-REIVAC;
- contribution to several structuring projects carried out with LMICs, such as UNITY (mpox), INTEGRATE (Lassa), or EBOPEP (Ebola);
- strengthened partnerships with leading European stakeholders, such as GloPID-R (*Global Research Collaboration for Infectious Disease Preparedness*) and EDCTP (*European and Developing Countries Clinical Trials Partnership*).

➤ A closer partnership with the WHO

ANRS MIE works in close, direct collaboration with the World Health Organisation (WHO) on numerous projects. This collaboration was formalised in 2025 when the agency was designated a WHO Collaborating Centre for Emerging Infectious Diseases.

ANRS MIE manages the WHO *Collaborative Open Research Consortium* (CORC) on Filoviruses (Ebola, Marburg). This cooperation has already led to the publication of international recommendations in January 2025 for the management of the Marburg virus, developed under the joint auspices of ANRS MIE and WHO.

The partnership is governed by a memorandum of understanding establishing long-term collaboration on all major shared scientific priorities.

ANRS MIE supports the international visibility of French research in the fight against infectious diseases.

➤ A continuously expanding international network

Since 1988, ANRS, and then ANRS MIE, has built a global network of scientific cooperation based on reciprocity, co-construction and local engagement.

Research partnerships have been established by ANRS in Africa (Burkina Faso, Cameroon, Côte d'Ivoire, Egypt, Senegal, South Africa), Asia (Cambodia, Vietnam) and Latin America (Brazil).


Since the creation of ANRS MIE in 2021, new partnerships have been formalised: in Guinea (2022), the Democratic Republic of the Congo (2023) and soon in Togo (2025), with the deployment of international research platforms in global health ("PRISME"). The "PRISME" model is an innovative model of scientific collaboration, as close as possible to needs in emerging situations.

ANRS MIE's international activities are carried out in close collaboration with the Directorate General for Globalisation of the Ministry for Europe and Foreign Affairs ("MEAE").

Discover the
International
Network



[https://
anrs.fr/en/
partnerships/
international-
network/](https://anrs.fr/en/partnerships/international-network/)





ANRS Emerging infectious diseases is an agency of researchers, for researchers: it removes barriers to research on infectious pathogens, facilitates it, supports it, and accompanies it.



Professor Yazdan Yazdanpanah,
Director of ANRS MIE

Key figures in 2025

155

Winners*

*including all projects,
research grants and
early-stage research
contracts

€100
million

mobilised for
research across
the entire scope
of ANRS MIE
thematic areas


21 **European
Countries**

engaged in
the European
partnership
Be Ready Plus
coordinated by
ANRS MIE

132

Employees

working within
the agency as
of June 2025



For more information
on ANRS MIE

<https://anrs.fr/en/>

ANRS Maladies infectieuses émergentes

PariSanté Campus | 2 rue d'Oradour-sur-Glane | 75015 Paris

Tél. : +33 (0)1 53 94 60 32

anrs
EMERGING INFECTIOUS
DISEASES **Inserm**